S D Marks1, C Pilkington, P Woo, M J Dillon. 1. Nephro-Urology Unit, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. s.marks@ich.ucl.ac.uk
Abstract
OBJECTIVES: The British Isles Lupus Assessment Group (BILAG) index is a standardized systemic lupus erythematosus (SLE) disease activity assessment. The main aim of this study was to correlate the BILAG index with laboratory measures of disease activity in childhood-onset SLE with and without biopsy-proven lupus nephritis. METHOD: Prospective observational comparison study of the BILAG index in 21 SLE patients under 18 yr of age over a 12-month period in a tertiary referral paediatric outpatient clinic. RESULTS: Eleven patients with lupus non-nephritis and 10 patients with lupus nephritis were reviewed. The lupus nephritis patients had significantly (P<0.001) more admissions over a similar time interval since diagnosis. The renal BILAG disease activity scores were significantly greater (P = 0.013) in the lupus nephritis group (range 1-9, median 3.0, compared with 0-3 and 1.0 in the lupus non-nephritis group). The total BILAG scores and patient visual analogue scores (VAS) were higher in the lupus nephritis groups, unlike the lower physician VAS, but these differences were not statistically significant compared with other laboratory indices of disease activity. CONCLUSIONS: The BILAG index is a useful tool in monitoring disease activity in children and adolescents with SLE. The data collected for the BILAG index can be used serially and effectively by different clinicians over time to enable recording of disease status at sequential assessments. The lower patient VAS in the lupus non-nephritis group was not significant and may reflect the patients' own perception of lethargy at times of increased disease activity.
OBJECTIVES: The British Isles Lupus Assessment Group (BILAG) index is a standardized systemic lupus erythematosus (SLE) disease activity assessment. The main aim of this study was to correlate the BILAG index with laboratory measures of disease activity in childhood-onset SLE with and without biopsy-proven lupus nephritis. METHOD: Prospective observational comparison study of the BILAG index in 21 SLEpatients under 18 yr of age over a 12-month period in a tertiary referral paediatric outpatient clinic. RESULTS: Eleven patients with lupus non-nephritis and 10 patients with lupus nephritis were reviewed. The lupus nephritispatients had significantly (P<0.001) more admissions over a similar time interval since diagnosis. The renal BILAG disease activity scores were significantly greater (P = 0.013) in the lupus nephritis group (range 1-9, median 3.0, compared with 0-3 and 1.0 in the lupus non-nephritis group). The total BILAG scores and patient visual analogue scores (VAS) were higher in the lupus nephritis groups, unlike the lower physician VAS, but these differences were not statistically significant compared with other laboratory indices of disease activity. CONCLUSIONS: The BILAG index is a useful tool in monitoring disease activity in children and adolescents with SLE. The data collected for the BILAG index can be used serially and effectively by different clinicians over time to enable recording of disease status at sequential assessments. The lower patientVAS in the lupus non-nephritis group was not significant and may reflect the patients' own perception of lethargy at times of increased disease activity.
Authors: Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M Huber; David A Cabral; Rosie Scuccimarri; Paivi M Miettunen; Johannes Roth; Stephanie A Atkinson; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; Maryann Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: Arthritis Care Res (Hoboken) Date: 2012-01 Impact factor: 4.794
Authors: A M Huber; I Gaboury; D A Cabral; B Lang; A Ni; D Stephure; S Taback; P Dent; J Ellsworth; C LeBlanc; C Saint-Cyr; R Scuccimarri; J Hay; B Lentle; M Matzinger; N Shenouda; D Moher; F Rauch; K Siminoski; L M Ward Journal: Arthritis Care Res (Hoboken) Date: 2010-04 Impact factor: 4.794
Authors: Claire M A LeBlanc; Jinhui Ma; Monica Taljaard; Johannes Roth; Rosie Scuccimarri; Paivi Miettunen; Bianca Lang; Adam M Huber; Kristin Houghton; Jacob L Jaremko; Josephine Ho; Nazih Shenouda; Mary Ann Matzinger; Brian Lentle; Robert Stein; Anne Marie Sbrocchi; Kiem Oen; Celia Rodd; Roman Jurencak; Elizabeth A Cummings; Robert Couch; David A Cabral; Stephanie Atkinson; Nathalie Alos; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Bone Miner Res Date: 2015-05-26 Impact factor: 6.741
Authors: Louise Watson; Kjell Tullus; Clarissa Pilkington; Christine Chesters; Stephen D Marks; Paul Newland; Caroline A Jones; Michael W Beresford Journal: Pediatr Nephrol Date: 2013-11-16 Impact factor: 3.714
Authors: Lucy Ballantine; Angela Midgley; David Harris; Ella Richards; Sarah Burgess; Michael W Beresford Journal: Pediatr Rheumatol Online J Date: 2015-04-10 Impact factor: 3.054
Authors: Eve Mary Dorothy Smith; Andrea Lyn Jorgensen; Angela Midgley; Louise Oni; Beatrice Goilav; Chaim Putterman; Dawn Wahezi; Tamar Rubinstein; Diana Ekdawy; Rachel Corkhill; Caroline Ann Jones; Stephen David Marks; Paul Newland; Clarissa Pilkington; Kjell Tullus; Michael William Beresford Journal: Pediatr Nephrol Date: 2016-09-03 Impact factor: 3.714
Authors: Lucy E Ballantine; Joanne Ong; Angela Midgley; Louise Watson; Brian F Flanagan; Michael W Beresford Journal: Pediatr Rheumatol Online J Date: 2014-01-16 Impact factor: 3.054